Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Shih-Jen Liu, Ph. D.

Assistant investigator
Vaccine Research and Development Center
levent@nhri.org.tw

EDUCATION

  • Ph.D., Life Science, National Defense Medical Center, Taiwan, 1998
  • M.S., Pharmacology, National Cheng Kung University, Taiwan, 1993
  • B.S., Pharmacy, Kaohsiung Medical College, Taiwan, 1989

    PROFESSIONAL EXPERIENCES

  • Adjunct Assistant Professor, Department of Biotechnology, National Chiao Tung University, Taiwan (2007-present)
  • Assistant Investigator, Vaccine Research and Development Center, National Health Research Institutes, Taiwan (2006-present)
  • Visiting Scholar, Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, USA (2006)
  • Adjunct Assistant Professor, Department of Biotechnology, Ming Chuan University, Taiwan (2005-present)
  • Research Associate, Vaccine Research & Development Center, National Health Research Institutes, Taiwan (2004-2006)
  • Director, Department of R&D, Anawrahta Biotech. Co. Taiwan (2001-2003)
  • Scientist, Department of R&D, Anawrahta Biotech. Co. Taiwan (1998-2001)

    RESEARCH INTERESTS

    Dr. Liu’s research interests include discovery of human CTL epitopes to develop therapeutic vaccine and development of human papilloma virus vaccine, dendritic cells-based immunotherapy. His laboratory created HLA- transgenic mice model and established a MHC class I tetramer platform. These technologies could be applied to clinical immune monitoring and vaccine development. In the future, he will develop prophylactic and therapeutic HPV vaccine for Asian population.

    RESEARCH ACTIVITIES & ACCOMPLISHMENTS

    Dr. Liu has established a GLP-grade dendritic cell culture technology for clinical trial in Anawrahta company. He collaborated with Dr. Chi Kwan-Hwa to conduct a phase I trial “Phase I Trial of Combination of Conformal Radiotherapy and Intra-Tumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma”. The result was published in J. Immunotherapy. He also got two SBIR grants from Ministry of economic affairs. One is “Vector development for cancer DNA vaccine”, the other one is “Immunoadsorption device”. The immunoadsorption device patent has been issued.

    SELECTED PUBLICATIONS

    1.Chen HW, Liu SJ, Chong P, Sia C. The Development and Application of HLA Tetramers in the Detection, Characterization and Therapy of Type 1 Diabetes Mellitus. Rev. Diabetic studies. 3: 51-6, 2007.

    2.Lien SP, Shih YP, Chen HW, Tsai JP, Leng CH, Lin MH, Lin LH, Liu SY, Chou AH, Chang YW, Chen YM, Chong P, Liu SJ*. Identification of Synthetic Vaccine Candidates against SARS CoV Infection. Biochem. Biophy. Res. Commun. 358: 716-21, 2007.

    3.Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC, Chou AH, Chang SR, Hsiao KN, Yu FW, Chen HW. Induction of a Distinct CD8 Tnc17 Subset by Transforming Growth Factor-? and Interleukin-6. Journal of Leukocyte Biology. 82: 354-60, 2007.

    4.Shih YP, Chen CY, Liu SJ, Chen KH, Lee YM, Chao YC, Chen YM. Identification of the epitopes responsible for neutralizing antibody and DCSIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J. Virol. 80:10315-10324, 2006.

    5.Liu SJ, Leng CH, Lien SP, Chi HY, Huang CY, Lin CL, Lian WC, Chen CJ, Hsieh SL, Chong P. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine. 24:3100-8, 2006.

    6.Lai SC, Chong P, Yeh CT, Liu SJ, Jan JT, Chi HY, Liu HW, Chen A, Wang YC. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV) J Biomed Sci. 12:711-27, 2005.

    7.Chi KH, Liu SJ, Li CH, Kuo HP, Wang YS, Chao Y, Hsieh SL. Phase I Trial of Combination of Conformal Radiotherapy and Intra-Tumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma. J. Immunotherapy. 28:129-135, 2005.

    PATENT

  • US patent No. 7,118,753 “Enhancing cell-based immunotherapy”, Granted 2006.
  • JP patent No.3719958; ROC patent No. I238251 “Extracorporeal immunoadsorption device”; Granted 2005.
  • US patent No. 6,843,990; PRC patent No. 195762 “Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof”; Granted 2005.
  • ROC patent No. I225097 “Anti-counterfeit biocode”; Granted 2004.
  • ROC patent No. 089125856 “Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof”; Granted 2003.